Zydus Hospira Oncology Pvt. Ltd., a 50: 50 joint venture company between Zydus Cadila and Hospira Inc., USA (now part of Pfizer Group) has received an Establishment Inspection Report (EIR) from the USFDA which concluded that the inspection is "closed" and states that the inspection classification of this facility is 'Voluntary Action Indicated' (VAI). The manufacturing plant had completed the USFDA audit from 5th to 12th April 2018.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.371.5 as compared to the previous close of Rs. 382.1. The total number of shares traded during the day was 156050 in over 2205 trades.
The stock hit an intraday high of Rs. 383.55 and intraday low of 369. The net turnover during the day was Rs. 58566796.